Welcome to our dedicated page for ANGIODYNAMICS SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANGIODYNAMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANGIODYNAMICS's regulatory disclosures and financial reporting.
AngioDynamics, Inc. (NASDAQ: ANGO) filed a Form 8-K on July 15, 2025 to furnish—rather than file—materials related to its fiscal fourth-quarter and full-year results ended May 31, 2025.
- Item 2.02: The company issued a press release (Exhibit 99.1) announcing its Q4 and FY 2025 financial performance.
- Item 7.01: Investor presentation slides (Exhibit 99.2) discussing the same period were also provided.
- Both exhibits are expressly excluded from Exchange Act Section 18 liability and will not be incorporated into future Securities Act or Exchange Act filings unless specifically referenced.
- No quantitative results, guidance, or commentary appear in the 8-K text itself; investors must review the furnished exhibits for details.
The filing contains standard forward-looking-statement disclaimers and lists common risk factors that could cause actual results to differ.